LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy ...

Time in range is a powerful metric for modern diabetes management - but a new survey finds less than half of people with insulin-treated diabetes are even using it.1 A recent UK survey found that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Dexcom One system combines the fingerstick-free glucose tracking of the company’s other CGM systems with a pared-down software platform, resulting in lower prices for the disposable system.

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy 1, reinforcing the need to broaden ...

DexCom (NasdaqGS:DXCM) reported new clinical data from its CONNECT trial on the Dexcom G7 continuous glucose monitoring system in adults with Type 2 diabetes not using insulin. The company introduced ...

DexCom, which has underperformed its medical equipment and S&P 500 peers in a big way in 2025, could be staring at better prospects next year. Stelo is facing vast and underpenetrated prediabetes and ...

The "direct-to-watch" feature eliminates the need to keep your phone near for readings. Dexcom is looking into other smartwatches too, the company's COO says. Jessica was a writer on the Wellness team ...

DexCom Inc, a leader in continuous glucose monitoring (CGM) technology, finds itself at a pivotal moment as it navigates supply chain challenges while pursuing growth opportunities in the expanding ...

LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an ...